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CD37 is a tetraspannin that triggers cell death and is a potential therapeutic target in cancers. In this issue of
Cancer Cell, Lapalombella et al. show that CD37 is tyrosine phosphorylated following engagement by a biva-
lent engineered antibody fragment that binds CD37 and activates both SHP-1-dependent apoptotic signaling
and PI3K-AKT-mediated survival signaling.Small modular immuno-pharmaceuticals
(SMIP) are disulfide-linked dimers of
single-chain proteins comprised of one
antigen binding VH/VL, a connecting
hinge region, and an Fc (fragment, crystal-
lizable) region (CH2-CH3) (Figure 1).
Because of their smaller size, these candi-
date therapetics may have better tissue
penetration than monoclonal antibodies
(mAbs). SMIP-016 is a dimeric recombi-
nant single-chain polypeptide engineered
to exhibit the full binding activity of an anti-
CD37mAb but at one-third less of the size
(Zhao et al., 2007). Previous studies have
shown that SMIP-016 is a potent inducer
of apoptosis and antibody-dependent
cellular cytotoxicity in B-cell leukemia/
lymphoma cell lines and primary chronic
lymphocytic leukemia (CLL) cells and
is superior to the therapeutic antibodies
used in these diseases (Zhao et al.,
2007). TRU-016 is a humanized variant of
SMIP-016 and is currently undergoingSMIP-016
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Figure 1. SMIP-016 Is an Anti-CD37 Polypeptide
Comparison of SMIP-016 and an anti-CD37 mAb. VH, variable
heavy chain; VL, variable light chain; CH, constant heavy
chain.clinical trials for patients with CLL
(http://www.clinicaltrials.gov).
CLL is the most common type of
leukemia. To date, the anti-CD20
mAb Rituximab remains the most
widely used mAb in the treatment
of CLL. A high response rates of
51% with 4% complete response
(CR) were achieved when Rituximab
was used in previously untreated
patients with CLL (Hainsworth
et al., 2003). SMIP-016 acts by
a mechanism distinct from Rituxi-
mab, inducing caspase indepen-
dent and tyrosine phosphorylation-
dependent apoptosis (Zhao et al.,
2007). Thus, it was not surpris-
ing that TRU-016 and Rituximab
showed complementary activity
(Robak et al., 2009).
CD37 is a four transmembrane
glycoprotein expressed at highlevels on B cells and to a lesser extent
on T cells and myeloid cells (Barrena
et al., 2005). The physiological ligand for
CD37 is unknown, though it is shown
that CD37 interacts with the C-type lectin
dectin-1. Dectin-1 recognizes b-glucans
found in cell walls of fungi. It is possible
that together with dectin-1, CD37 forms
a pattern-recognition-receptor for path-
ogen-associated molecule pattern.
Indeed, CD37/ mice are better pro-
tected from Candida albicans infection
than WT mice (van Spriel et al., 2009).
CD37 belongs to the tetraspanin pro-
tein family and associates with other
tetraspanins, such as CD53, CD81, and
CD82 to form multiprotein complexes,
the so-called tetraspanin web, on cell
surfaces (Tarrant et al., 2003). Like other
tetraspanins, CD37 has short cytoplasmic
tails (8–14 aa) that lack typical signaling
domains. CD37/ mice display impaired
T cell-dependent antibody responsesCancer Cel(Knobeloch et al., 2000) and increased
dendritic cell antigen-presenting capacity
(Sheng et al., 2009).
In this issue of Cancer Cell, Lapalom-
bella et al. (2012) show that CD37 has
intrinsic tyrosine-based signaling ca-
pacity that is important for SMIP-016
induced apoptosis in primary CLL cells.
SMIP-016-induced apoptosis in CLL
patients’ samples depends upon tyrosine
phosphorylation (Zhao et al., 2007). The
authors started their investigation by
identifying tyrosine phosphorylated pro-
teins associated with CD37 upon SMIP-
016 stimulation. One of the targets they
identified is the SH-2-containing tyrosine
phosphatase SHP-1. They showed that
reducing SHP-1 expression dramatically
decreases SMIP-016 induced apoptosis
in CLL samples. SHP-1 downregulates
signaling pathways that promote pro-
liferation, and it is considered a tumor
suppressor (Wu et al., 2003). The authorsl 21, Mthen explored how SHP-1 is re-
cruited to CD37. They noticed that
the N-terminal cytoplasmic tail of
CD37 contains a weak S/I/V/
LxYxxI/V/L immuno-tyrosine inhibi-
tory motif (ITIM) that is known to
bind the SH2 domains of SHP-1.
Using biochemistry, mass spec-
trometry, and mutagenesis ap-
proaches, the authors convincingly
demonstrate that CD37 itself is tyro-
sine phosphorylated upon SMIP-
016 stimulation. Furthermore, most
of this phosphorylation occurs on
the N-terminal ITIM motif. A Y13 to
F13 CD37 ITIM mutant does not
bind SHP-1, and SMIP-016 is less
effective in killing cells expressing
this mutant.
Exploring other functional con-
sorts, the authors found that
the C-terminal cytoplasmic tail ofay 15, 2012 ª2012 Elsevier Inc. 597
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PreviewsCD37, which contains two additional
tyrosines Y274 and Y280, somehow inhibits
CD37 phosphorylation and the cytotoxic
effects of SMIP-016. This led to the
finding that SMIP-016 also activates the
PI3K-AKT proliferative signaling pathway.
Treatment of cells with the PI3K inhibitor
LY294002 or deleting the C-terminal tail
of CD37 increases SMIP-016-induced
killing. In summary, SMIP-016 simulta-
neously activates both SHP-1 mediated
death signaling and PI3K-AKT mediated
survival signaling.
The study of Lapalombella et al. (2012)
not only provides deeper insight into
the molecular mechanisms of SMIP-016
action but may also help guide current
and future clinical trials using TRU-016.
For example, the current study reveals
an opposing role for PI3K and an absolute
requirement for SHP-1 expression for
efficacy of SMIP-016. Consistent with
its tumor suppressor role, expression of598 Cancer Cell 21, May 15, 2012 ª2012 ElsSHP-1 is diminished or absent in many
leukemias and lymphomas (Wu et al.,
2003). Thus, it can be expected that
cancers with low or no SHP-1 expression
may not respond to TRU-016 treatment.
The results from current TRU-016 clinical
trials on CLL are expected in the first
half of 2013, and in interpreting the
outcome, it may be useful to stratify
subjects based on the SHP-1 expression
level and the PI3K pathway activity in their
tumors.
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In a recent issue of Cell, Kumar and colleagues uncovered a synthetic lethal interaction between oncogenic
KRAS and the transcription factor GATA2 in non-small cell lung carcinoma. Pharmacological inhibition
of GATA2-mediated pathways with bortezomib and fasudil results in dramatic tumor inhibition. These obser-
vations unveil new armamentaria to fight this deadly disease.Non-small cell lung carcinoma (NSCLC)
hasoneof thehighest incidenceand lowest
survival rates, a combination that makes
this tumor type one of the deadliest human
cancers. At least a quarter of NSCLC
expressamutantKRASallele that encodes
a constitutively active small G protein
known tosignal throughaseriesof kinases.
While these kinases are in principle ame-
nable to pharmacological intervention,
a selective treatment for KRAS mutant
NSCLC is not yet available in the clinic.
During the last decade, there have been
significant efforts directed to reproducethe natural history of NSCLC in genetically
engineered mouse (GEM) models (Heyer
et al., 2010). Recently, these models have
been utilized to evaluate potential thera-
peutic targets. Some of the validated
targets include well-known downstream
elements of KRAS signaling such as
components of the mitogenic RAF/MEK/
ERK cascade and the PI3K/AKT survival
pathway, most of which are druggable
kinases (Gupta et al., 2007; Engelman
et al., 2008;Blasco et al., 2011) (Figure 1A).
However, these studies cannot be directly
extrapolated to the clinic because targetablation occurred during tumor initiation
rather than during tumor progression.
Moreover, these Kras oncogene-driven
GEM models retained the full component
of tumor suppressors and, hence, do not
develop metastatic tumors.
Other studies have attempted to vali-
date pathways less directly linked to
KRAS signaling. In one study, elimination
of CDK4, but not the other interphase
CDKs, elicited a rapid senescence
response that resulted in partial tumor
regression, an observation validated with
clinically available CDK4 inhibitors (Puyol
